Back to News

Hatch-Waxman 101: Safe Harbor

Previously Recorded

Pacific Time

Cooley lawyers will discuss the development and current scope of Safe Harbor under 35 U.S.C. § 271(e)(1), and the practical impact of Safe Harbor considerations on Hatch-Waxman and other pharmaceutical patent litigation. We will also address its impacts on freedom to operate and licensing considerations during product development and fundraising.  

For more information or to request access to the program recording, please email email Maria Russo

Related Contacts
Sanya Sukduang  Partner Washington, DC
Jonathan Davies  Partner Washington, DC